Induction of “natural killer” cells by BCG

Abstract

THE past decade has witnessed numerous attempts to suppress tumour growth by the administration of immune stimulants. Notable successes have been achieved, particularly following the intralesional injection of Bacille Calmette-Guérin (BCG) which has been observed to cause the regression of local tumour nodules in both experimental animals1,2 and man3–5. Although there is some controversy as to the mode of action of BCG, it has become widely accepted that its anti-tumour effects are principally mediated through host macrophages, “activated” by the immunostimulant6–8. Observations we have recently made in studies of the peritoneal exudates of BCG-infected mice suggest an alternative possibility: that tumour destruction is caused by a non-macrophage population of cytotoxic cells which is induced by BCG immunisation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Zbar, B., Bernstein, I. D., Bartlett, G. L., Hanna, M. G., Jr, and Rapp, H. J., J. natn. Cancer Inst., 49, 119–130 (1972).

  2. 2

    Baldwin, R., and Pimm, M., Br. J. Cancer, 28, 281–287 (1972).

  3. 3

    Morton, D. L., Seminars in Oncology, 1, 297–310 (1974).

  4. 4

    Laucius, J. F., Bodurtha, A. J., Mastrangelo, M. J., and Creech, R. H., J. Reticuloendothel. Soc., 16, 347–373 (1974).

  5. 5

    Bast, R. C., Jr, Zbar, B., Borsos, T., and Rapp, H. J., New Engl. J. Med., 290, 1413–1420, 1458–1469 (1974).

  6. 6

    Alexander, P., Natn. Cancer Inst. Mongraph, 39, 127–133 (1973).

  7. 7

    Hibbs, J. B., Jr, Science, 180, 868–870 (1973).

  8. 8

    Germain, R. N., Williams, R. M., and Benacerraf, B., J. natn. Cancer Inst., 54, 709–720 (1975).

  9. 9

    Thorn, R. M., Palmer, J. C., and Manson, L. A., J. Immun. Meth., 4, 301–315 (1974).

  10. 10

    Kiessling, R., et al., J. exp. Med., 143, 772–780 (1976).

  11. 11

    Herberman, R., Nunn, M., and Lavrin, D., Int. J. Cancer, 16, 216–229 (1975).

  12. 12

    Herberman, R., Nunn, M., Holden, H., and Lavrin, P., Int. J. Cancer, 16, 230–239 (1975).

  13. 13

    Kiessling, R., Klein, E., Pross, H., and Wigzell, H., Eur. J. Immun., 5, 117–121 (1975).

  14. 14

    Lundgren, G., Zukosi, C. F., and Möller, G., Clin. exp. Immun., 3, 817–836 (1968).

  15. 15

    Kamat, R., and Henney, C. S., J. Immun., 115, 1592–1598 (1975).

  16. 16

    Cerottini, J.-C., Engers, H., MacDonald, H., and Brunner, K. T., J. exp. Med. 140, 703–717 (1974).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.